| References
|  |
|
| 110 | Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine improves small-vessel coronary endothelial function in humans. Circulation 1998;97:2123-8. |
| 116 | Adams MR, McCredie R, Jessup W, et al. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997;129:261-9. |
| 184 | Koshy KM, Griswold E, Schneeberger EE. Interstitial nephritis in a patient taking creatine. N Engl J Med 1999;340:814-5. |
| 406 | Upton R, ed. Hawthorn Leaf with Flower: Analytical, quality control, and therapeutic monograph. Santa Cruz, CA: American Herbal Pharmacopoeia 1999:1-29. |
| 1284 | Shimon I, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995;98:485-90. |
| 1285 | Pfitzenmeyer P, Guilland JC, d'Athis P, et al. Thiamine status of elderly patients with cardiac failure including the effects of supplementattion. Int J Vitam Nutr Res 1994;64:113-8. |
| 1286 | Seligmann H, Halkin H, Rauchfleisch S, et al. Thiamine deficiency in patients with congestive heart failure receiving long-term furosemide therapy: a pilot study. Am J Med 1991;91:151-5. |
| 1362 | Creager MA, Gallagher SJ, Girerd XJ, et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53. |
| 1363 | Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 1996;97:1989-94. |
| 1439 | Siliprandi N, Di Lisa F, Menabo R. Propionyl-L-carnitine: biochemical significance and possible role in cardiac metabolism. Cardiovasc Drugs Ther 1991;5 Suppl 1:11-5. |
| 1572 | Bartels GL, Remme WJ, Pillay M, et al. Acute improvement of cardiac function with intravenous L-propionylcarnitine in humans. J Cardiovasc Pharmacol 1992;20:157-64. |
| 1575 | Anand I, Chandrashekhan Y, De Giuli F, et al. Acute and chronic effects of propionyl-L-carnitine on the hemodynamics, exercise capacity, and hormones in patients with congestive heart failure. Cardiovasc Drugs Ther 1998;12:291-9. |
| 1582 | Caponnetto S, Canale C, Masperone MA, et al. Efficacy of L-propionylcarnitine treatment in patients with left ventricular dysfunction. Eur Heart J 1994;15:1267-73. |
| 1583 | Mancini M, Rengo F, Lingetti M, et al. Controlled study on the therapeutic efficacy of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-4. |
| 2118 | Pritchard NR, Kalra PA. Renal dysfunction accompanying oral creatine supplements. Lancet 1998;351:1252-3. |
| 2128 | Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;334:1372-3. |
| 2504 | Bharani A, Ganguly A, Bhargava KD. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure. Int J Cardiol 1995;49:191-9. |
| 3330 | Tenebaum A, Fisman EZ, Motro M. L-arginine: Rediscovery in progress. Cardiology 1998;90:153-5. |
| 3467 | Niittynen L, Nurminen ML, Korpela R, et al. Role of arginine, taurine, and homocysteine in cardiovascular diseases. Ann Med 1999;31:318-26. |
| 3595 | Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996;93:2135-41. |
| 3596 | Watanabe G, Tomiyama H, Doba N. Effects of oral administration of L-arginine on renal function in patients with heart failure. J Hypertens 2000;18:229-34. |
| 3625 | Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J 2000;139:S120-3. |
| 3626 | Ghidini O, Azzurro M, Vita G, Sartori G. Evaluation of the therapeutic efficacy of L-carnitine in congestive heart failure. Int J Clin Pharmacol Ther Toxicol 1988;26:217-20. |
| 4562 | Andrews R, Greenhaff P, Curtis S, et al. The effect of dietary creatine supplementation on skeletal muscle metabolism in congestive heart failure. Eur Heart J 1998;19:617-22. |
| 4563 | Gordon A, Hultman E, Kaijser L, et al. Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 1995;30:413-8. |
| 5090 | Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med 2000;132:636-40. |
| 5248 | Azuma J, Sawamura A, Awata N. Usefulness of taurine in chronic congestive heart failure andits prospective application. Jpn Circ J 1992;56:95-9. |
| 5271 | Azuma J, Sawamura A, Awata N, et al. Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial. Clin Cardiol 1985;8:276-82. |
| 5306 | Azuma J, Hasegawa H, Sawamura A, et al. Therapy of congestive heart failure with orally administered taurine. Clin Ther 1983;5:398-408. |
| 6028 | Hambrecht R, Hilbrich L, Erbs S, et al. Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J Am Coll Cardiol 2000;35:706-13. |
| 6037 | Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol 1999;33:1549-52. |
| 6038 | Permanetter B, Rossy W, Klein G, et al. Ubiquinone (coenzyme Q10) in the long-term treatment of idiopathic dilated cardiomyopathy. Eur Heart J 1992;13:1528-33. |
| 6048 | Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000;57:1221-7. |
| 6199 | Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. [Article in Danish]. Ugeskr Laeger 1998;160:3226-7. |
| 6407 | Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: A long-term, multicenter, randomized study. Clin Investig 1993;71:S134-6. |
| 6408 | Hofman-Bang C, Rehnqvist N, Swedberg K, et al. Coenzyme Q10 as an adjunctive treatment of congestive heart failure. J Card Fail 1995;1:101-7. |
| 6409 | Baggio E, Gandini R, Plauncher AC, et al. Italian multicenter study on the safety and efficacy of coenzyme Q10 as adjunctive therapy in heart failure. CoQ10 Drug Surveillance Investigators. Mol Aspects Med 1994;15 Suppl:S287-94. |
| 6430 | Anderson PO, Knoben JE. Handbook of Clinical Drug Data. 8th ed. Stamford, CT: Appleton & Lange, 1997. |
| 7813 | Kanaya Y, Nakamura M, Kobayashi N, Hiramori K. Effects of L-arginine on lower limb vasodilator reserve and exercise capacity in patients with chronic heart failure. Heart 1999;81:512-7. |
| 7820 | Wu G, Meininger CJ. Arginine nutrition and cardiovascular function. J Nutr 2000;130:2626-9. |
| 8014 | Chin-Dusting JP, Kaye DM, Lefkovits J, et al. Dietary supplementation with L-arginine fails to restore endothelial function in forearm resistance arteries of patients with severe heart failure. J Am Coll Cardiol 1996;27:1207-13. |
| 8219 | Paasonen MK, Penttila O, Himberg JJ, et al. Platelet taurine in patients with arterial hypertension, myocardial failure or infarction. Acta Med Scand Suppl 1980;642:79-84. |
| 8221 | Azuma J. Long-term effect of taurine in congestive heart failure: Preliminary report. Adv Exp Med Biol 1994;359:425-33. |
| 8222 | Azuma J, Takihara K, Awata N, et al. Taurine and failing heart: experimental and clinical aspects. Prog Clin Biol Res 1985;179:195-213. |
| 8279 | Schmidt U, Kuhn U, Ploch M, Hubner WD. Efficacy of the Hawthorne (Crataegus) Preparation LI 132 in 78 patients with chronic congestive heart failure defined as NYHA functional class II. Phytomedicine 1994;1:17-24. |
| 8280 | Zapfe jun G. Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II. Phytomedicine 2001;8:262-6. |
| 8310 | Aviram M, Dornfeld L. Pomegranate juice consumption inhibits serum angiotensin converting enzyme activity and reduces systolic blood pressure. Atherosclerosis 2001;158:195-8. |
| 8909 | Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997;18:S159-68. |
| 9613 | Ryan MP. Diuretics and potassium/magnesium depletion: directions for treatment. Am J Med 1987;82:38-47. |
| 9614 | Hollifield JW. Magnesium depletion, diuretics, and arrhythmias. Am J Med 1987;82:30-7. |
| 9900 | Huxtable R, Bressler R. Elevation of taurine in human congestive heart failure. Life Sci 1974;14:1353-9. |
| 10144 | Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003;114:665-74. |
| 10506 | Levy WC, Soine LA, Huth MM, Fishbein DP. Thiamine deficiency in heart failure (letter). Am J Med 1992;93:705-6. |
| 10507 | Leslie D, Gheorghiade M. Is there a role for thiamine supplementation in the management of heart failure. Am Heart J 1996;131:1248-50. |
| 10508 | Saif MW. Is there a role for thiamine in the management of congestive heart failure? (letter) South Med J 2003;96:114-5. |
| 11449 | Degenring FH, Suter A, Weber M, Saller R. A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II. Phytomedicine 2003;10:363-9. |
| 11450 | Schwinger RH, Pietsch M, Frank K, Brixius K. Crataegus special extract WS 1442 increases force of contraction in human myocardium cAMP-independently. J Cardiovasc Pharmacol 2000;35:700-7. |
| 12170 | Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol 2004;27:295–9. |
| 12316 | Sonnenblick E. Detecting and treating heart failure: An update on strategies. www.ConsultantLive.com (Accessed 24 January 2001). |
| 12317 | Skrabal M, Stading J, Behmer-Miller K, et al. Advances in the treatment of congestive heart failure: New approaches for an old disease. Pharmacotherapy 2000;20:787-804. |
| 12318 | Pharmacotherapy Self-Assessment Program. Module 1: Cardiology. 3rd Ed. Kansas City, MO: American College of Clinical Pharmacy, 1998. |
| 12319 | Adams KF, Baughman KL, Konstam MA, et al. Heart failure society guidelines: A model of consensus and excellence. Pharmacotherapy 2000;20:495-522. |
| 12320 | Valsartan for heart failure. Pharmacist's Letter / Prescriber's Letter 2000;17(1):170104. |
| 12321 | Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. |
| 12322 | McMurray JJ, O'Meara E. Treatment of heart failure with spironolactone--trial and tribulations. N Engl J Med 2004;351:526-8. |
| 12323 | El-Aroussy W, et al. Plasma carnitine levels as a marker of impaired ventricular function. Mol Cell Biochem 2000;213:37-41. |
| 15331 | Vogelsang A. Ornithogalum umbellatum in the treatment of congestive heart failure: progress report. J Am Geriatr Soc 1961;9:1096-9. |
| 15332 | Vogelsang A. Clinical trial of Ornithogalum umbellatum on the human heart; preliminary report. Can Med Assoc J 1955;73:295-6. |